Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. / Kimer, Nina; Krag, Aleksander; Gluud, Lise L.
I: Patient Preference and Adherence, Bind 8, 2014, s. 331-338.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
AU - Kimer, Nina
AU - Krag, Aleksander
AU - Gluud, Lise L
PY - 2014
Y1 - 2014
N2 - Hepatic encephalopathy is a complex disease entity ranging from mild cognitive dysfunction to deep coma. Traditionally, treatment has focused on a reduction of ammonia through a reduced production, absorption, or clearance. Rifaximin is a nonabsorbable antibiotic, which reduces the production of ammonia by gut bacteria and, to some extent, other toxic derivatives from the gut. Clinical trials show that these effects improve episodes of hepatic encephalopathy. A large randomized trial found that rifaximin prevents recurrent episodes of hepatic encephalopathy. Most patients were treated concurrently with lactulose. Trials have varied greatly in design, outcomes, and duration of treatment regimes. Although a number of retrospective studies have indicated that long-term treatment with rifaximin is safe and possibly beneficial, high quality trials are needed to further clarify efficacy and safety of long-term treatment with rifaximin and evaluate effects of combination therapy with lactulose and branched-chain amino acids for patients with liver cirrhosis and hepatic encephalopathy.
AB - Hepatic encephalopathy is a complex disease entity ranging from mild cognitive dysfunction to deep coma. Traditionally, treatment has focused on a reduction of ammonia through a reduced production, absorption, or clearance. Rifaximin is a nonabsorbable antibiotic, which reduces the production of ammonia by gut bacteria and, to some extent, other toxic derivatives from the gut. Clinical trials show that these effects improve episodes of hepatic encephalopathy. A large randomized trial found that rifaximin prevents recurrent episodes of hepatic encephalopathy. Most patients were treated concurrently with lactulose. Trials have varied greatly in design, outcomes, and duration of treatment regimes. Although a number of retrospective studies have indicated that long-term treatment with rifaximin is safe and possibly beneficial, high quality trials are needed to further clarify efficacy and safety of long-term treatment with rifaximin and evaluate effects of combination therapy with lactulose and branched-chain amino acids for patients with liver cirrhosis and hepatic encephalopathy.
U2 - 10.2147/PPA.S41565
DO - 10.2147/PPA.S41565
M3 - Review
C2 - 24672227
VL - 8
SP - 331
EP - 338
JO - Patient Preference and Adherence
JF - Patient Preference and Adherence
SN - 1177-889X
ER -
ID: 138622724